• Pazopanib Hydrochloride: From Kinase Map to Translation

  2026-09-22

  Pazopanib Hydrochloride, also known as GW786034, is more than an anti-angiogenic agent: it is a translational probe for studying how coordinated receptor tyrosine kinase blockade reshapes tumor, endothelial, and stromal biology. This article connects its multi-target mechanism with improved in vitro response metrics and strategic model selection for renal cell carcinoma and soft tissue sarcoma research.

• hiPSC Intestinal Organoids for Pharmacokinetic Studies

  2026-09-22

  Saito and colleagues developed an accessible direct 3D culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoid-derived epithelial cells retained differentiated intestinal lineages and displayed drug-metabolizing enzyme and transporter activities, supporting more human-relevant absorption and pharmacokinetic studies.

• hiPSC Intestinal Organoids for Pharmacokinetic Studies

  2026-09-21

  Saito and colleagues established a direct three-dimensional cluster-culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids could be propagated, cryopreserved, and differentiated into intestinal epithelial cells with enterocyte-associated metabolic and transporter activities, supporting more human-relevant pharmacokinetic studies.

• Pazopanib (GW-786034) in ATRX Glioma Assays

  2026-09-21

  Pazopanib (GW-786034) provides a practical multi-targeted RTK probe for connecting ATRX status with receptor signaling, glioma viability, and combination responses. This guide translates the reference study into reproducible dose-response, pathway, angiogenesis, and tumor growth suppression workflows while emphasizing controls and troubleshooting.

• Cy3 TSA Fluorescence System Kit for Receptor Mapping

  2026-09-20

  The Cy3 TSA Fluorescence System Kit connects ultrasensitive fluorescence imaging with modern receptor biology. This guide explains how tyramide chemistry can support spatial validation of low-abundance targets while preserving the mechanistic insights gained from cryo-EM studies of class II olfactory receptors.

• FLOT1–FOSL2–EphA2 Axis in Alzheimer’s Disease

  2026-09-19

  A 2026 Neuropharmacology study identifies a FLOT1–FOSL2–EphA2 regulatory pathway that links microglial polarization with p38/MAPK signaling and neuroinflammation in an APP/PS1 model. Its integrated molecular, cellular, and behavioral evidence suggests that FLOT1 suppression can reduce pro-inflammatory microglial responses and improve spatial memory, while also highlighting important limits for translation to human Alzheimer’s disease.

• Targeted SPP1 Inhibition in Tumor-Associated Macrophages

  2026-09-18

  Kartal and colleagues developed a phenotypic small-molecule screen and TAM-avid CANDI nanocarrier strategy to reduce SPP1 expression in tumor-associated macrophages. The lead compound, CANDI460, lowered SPP1 in vitro and in vivo and produced tumor remissions in multiple murine models, providing a distinct alternative to broad macrophage depletion.

• Translating Tau Ser356 Biology Beyond Product Pages

  2026-09-18

  Tau phosphorylated at serine 356 is emerging as a mechanistically informative Alzheimer’s disease readout rather than merely another pathology-associated epitope. This article interprets the Taylor et al. preprint through a translational lens, explains what mouse and human brain-slice data do—and do not—establish, and positions Linagliptin (BI-1356) as an orthogonal comparator for carefully designed metabolic-neurodegeneration studies, not as a substitute for NUAK inhibition.

• N1-Methylpseudouridine: From Mechanism to Translation

  2026-09-17

  N1-Methylpseudouridine is becoming a strategic component of engineered mRNA, not merely a substitution for uridine. This thought-leadership article connects its effects on innate immune signaling, eIF2α-dependent translation control, codon optimization, and protein rescue in Niemann-Pick disease type C1 models to practical decisions in translational research.

• GW 4869: Exosome Workflow for Osteogenesis

  2026-09-17

  GW 4869 links neutral sphingomyelinase activity to extracellular-vesicle output, enabling researchers to test whether lithium-enhanced osteogenesis depends on exosomal Wnt10a delivery. This practical guide covers donor-cell treatment, EV normalization, mechanism-focused controls, and troubleshooting for BMSC–recipient assays.

• miRNA–mRNA Control of Juvenile Hormone Biosynthesis

  2026-09-16

  The reference study shows that coordinated suppression of specific microRNAs permits strong expression of juvenile hormone synthesis genes in the locust corpora allata during vitellogenesis. Transcriptomic, reporter-assay, and agomiR experiments connect this post-transcriptional switch with vitellogenin production and ovarian development, clarifying how adult insects generate the juvenile hormone levels required for reproduction.

• SPP1-Targeted TAM Inhibition and Tumor Reduction

  2026-09-16

  The reference study identifies a phenotypic small-molecule strategy for reducing SPP1 expression in tumor-associated macrophages and combines lead compounds with a TAM-avid polymeric nan formulation. Its results connect SPP1-high myeloid states with actionable tumor control in multiple murine models while highlighting the importance of cell-selective delivery.

• Cy3 TSA Fluorescence System Kit for IHC & ISH

  2026-09-15

  The Cy3 TSA Fluorescence System Kit extends conventional immunostaining into sensitive detection of low-abundance proteins, nucleic acids, and cell-surface signals. This practical guide connects tyramide signal amplification to intestinal barrier research, with workflow settings, assay controls, and troubleshooting strategies for reproducible fluorescence microscopy detection.

• Podocyte Exosomal HMGB1 in Lupus Nephritis

  2026-09-15

  The reference study identifies podocyte-derived exosomes carrying HMGB1 as a mechanistic link between podocyte activation and glomerular endothelial cell injury in lupus nephritis. Using pharmacologic, cargo-specific, genetic, and mouse-model experiments, it places TRIM27 downstream of exosomal HMGB1 and provides a framework for testing vesicle-mediated renal injury.

• ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors

  2026-09-14

  The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data further suggest that ATRX status may help interpret RTK inhibitor responses alongside temozolomide treatment, although clinical validation and direct target-mechanism studies remain necessary.

7986 records 1/533 page Next 12345 下5页 Last page